Characteristics and management of rheumatoid arthritis in France: Analysis of a representative French national claims database resulting in an estimated prevalence of 0.35%

Joint Bone Spine

Volumn 83, Issue 4, 2016, Pages 461-462

  Fautrel, Bruno ^a,b   Cukierman, Gabrielle ^c   Joubert, Jean Michel ^c   Laurendeau, Caroline ^d   Gourmelen, Julie ^e   Fagnani, Francis ^d  

^a INSTITUT PIERRE LOUIS D EPIDÉMIOLOGIE ET DE SANTÉ PUBLIQUE   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c UCB PHARMA   (Belgium)

^d CEMKA EVAL   (France)

^e CENTRE FOR RESEARCH IN EPIDEMIOLOGY AND POPULATION HEALTH   (France)

Author keywords

Biological agents; Comorbidity; DMARDs; Epidemiology; France; Prevalence; Rheumatoid arthritis

Indexed keywords

ADULT; AGED; AGING; COMORBIDITY; CONSULTATION; DATA BASE; FEMALE; FRANCE; HEALTH CARE UTILIZATION; HUMAN; ICD-10; LETTER; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRESCRIPTION; PREVALENCE; PUBLIC HEALTH INSURANCE; RHEUMATOID ARTHRITIS; RHEUMATOLOGY; AGE DISTRIBUTION; ARTHRITIS, RHEUMATOID; COMPARATIVE STUDY; CONFIDENCE INTERVAL; FACTUAL DATABASE; INCIDENCE; INSURANCE; MIDDLE AGED; ODDS RATIO; PROGNOSIS; PUBLIC HEALTH; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SEX RATIO; TREATMENT OUTCOME;

ANTIRHEUMATIC AGENT; BIOLOGICAL PRODUCT;

AGE DISTRIBUTION; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL PRODUCTS; CONFIDENCE INTERVALS; DATABASES, FACTUAL; FEMALE; FRANCE; HUMANS; INCIDENCE; INSURANCE CLAIM REVIEW; MALE; MIDDLE AGED; NATIONAL HEALTH PROGRAMS; ODDS RATIO; PROGNOSIS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SEX DISTRIBUTION; TREATMENT OUTCOME;

EID: 84949683581     PISSN: 1297319X     EISSN: 17787254     Source Type: Journal    
DOI: 10.1016/j.jbspin.2015.05.010     Document Type: Letter

References (8)

1. Mariette X., Gottenberg J.E., Ravaud P., et al. Registries in rheumatoid arthritis and autoimmune diseases: data from the French registries. Rheumatol (Oxford) 2011, 50:222-229.
2. Tuppin P., de Roquefeuil L., Weill A., et al. French national health insurance information system and the permanent beneficiaries sample. Rev Epidemiol Sante Publ 2010, 54:286-290.
3. Fautel B, Cukierman G, Joubert J-M, Laurendeau C, Gourmelen J, Fagnani F. Healthcare service utilisation costs attributable to rheumatoid arthritis in France: analysis of a representative national claims database (Part 2). Joint Bone Spine (in press).
4. CNAMTS Répartition et taux pour les principales maladies (CIM-10) des personnes en affection de longue durée (ALD 30 ou 31) pour le régime général (population prévalente), caractéristiques d'âge et de sexe 2009, Caisse nationale d'assurance maladie des travailleurs salariés (CNAMTS), Paris.
5. Guillemin F., Saraux A., Guggenbuhl P., et al. Prevalence of rheumatoid arthritis in France: 2001. Ann Rheum Dis 2005, 64:1427-1430.
6. Neovius M., Simard J.F., Askling J. Nationwide prevalence of rheumatoid arthritis and penetration of disease-modifying drugs in Sweden. Ann Rheum Dis 2011, 70:624-629.
7. Smolen J.S., Aletaha D., Bijlsma J.W., et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010, 69:631-637.
8. Gabriel S.E., Michaud K. Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases. Arthritis Res Ther 2009, 11:229.